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Abstract
BACKGROUND: The normoglycemic patients with diabetes risk and prediabetes have insulin resistance and 
consequently endothelial dysfunction that possible causes macroangiopathy and adverse cardiovascular events 
and further mortality of it. An early diabetes risk identification using not only prognostic scales but also biomarkers is 
starting and crucial point of struggle with 2 type diabetes mellitus and its complications.
AIM: The aim of the study is to estimate the impact of FABP4 biomarker on diabetes risk and cardiovascular events.
METHODS: A cross-sectional study was conducted simultaneously among 389 respondents aged 18–65 years. 
We provided survey and clinical examinations. The risk of diabetes was assessed using the FINDRISC scale and 
cardiovascular risk (CVR) was assessed using SCORE scale.
The serum FABP4 biomarker was studied using a multiplex assay, immunofluorescence using XMap technology, a 
Bioplex 3D instrument, and a MILLIPLEX® Human cardiovascular disease panel I reagent kit(Millipore). Results were 
considered statistically significant at p < 0.001.
RESULTS: The group of type 2 diabetes mellitus (T2DM) high risk was 79 (20%) of all study participants. The level of 
the FABP4 marker significantly prevailed in high-risk group of T2DM and high CVR was also established this group. 
We found a positive direct average correlation(r = 0.59; p = 0.000) between FABP4 and FINDRISC scale. The logistic 
regression analysis indicated that the level of the FABP4 marker increases withing the increased risk of T2DM. The 
correlation between FABP4 concentration and CVR according to the SCORE scale (r = 0.24; p = 0,000) was lower 
than between FABP4 and diabetes risk. Risk factors were established affecting on the increasing CVR by SCORE 
scale in patients with T2DM risk.
CONCLUSIONS: The level of FABP4 significantly prevailed in the group of diabetes and cardiovascular risk (CVR). 
The established correlations between FABP4 level and CVR or T2DM risk indicate on its increase in groups with a 
higher risk of type 2 diabetes and a high CVR.
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Introduction
Type 2 diabetes mellitus (T2DM) is one of the 
four priority non-communicable diseases. Measures are 
planned on prevention of diabetes, all over the world. 
During last few decades, the incidence and prevalence 
of diabetes have been increased dramatically. 
According to the International Diabetes Federation data 
in 2017 about 425 million of adults worldwide suffered 
from diabetes, compared to 108 million in 1980 [1]. 
The global diabetes incidence rate (standardized by 
age) has nearly doubled since 1980, rising from 4.7% 
to 8.5% in the population. The growth of diabetes 
incidence in the Republic of Kazakhstan from 2004 to 
2017 was 136.8% [2].
As well as high diabetes incidence, another 
352.1 million of people worldwide have a preliminary diabetes 
stage called Impair Glucose Tolerance. The health-care 
specialists expected that the number of prediabetic persons 
will increase till 531.6 million in 2045 [1]. This epidemiological 
situation was resulted from to the growth T2DM modifiable 
risk factors, such as overweight or obesity, malnutrition, 
and low physical activity. In 2016, T2DM caused 1.6 million 
deaths worldwide. The hyperglycemia caused another 2.2 
million deaths, increasing the risk of cardiovascular and 
other diseases [1].
The fundamental, prospective 20-years 
Framingham Heart Study shows the importance 
of association between the diabetes and the 
cardiovascular disease. The diabetes is one of risk 
factors of cardiovascular events, and it also doubles 
the age-related risk of cardiovascular disease in men, 
and triples in women [3]. The diabetes was the main 
independent risk factor of cardiovascular diseases, 
even after the relative risk was adjusted on such 
cofounders as age, arterial hypertension, smoking, 
hypercholesterolemia, and left ventricular hypertrophy.
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The starting point for a good struggle 
against diabetes is its early diagnostic. As longer 
person lives with hidden hyperglycemia without 
diabetes verification and treatment, the harder 
will be complications and mortality from this 
disease. Diabetes particularly, type 2, is completely 
asymptomatic, and frequently manifests with 
diabetic macroangiopathies, causing the CVR and 
the mortality from cardiovascular diseases. There 
are data that the development of cardiovascular 
complications of diabetes is caused by endothelial 
dysfunction that has a huge impact [4].
Nowadays, the search of sensitive and reliable 
biomarkers that simultaneously determines the risk of 
diabetes and the endothelial dysfunction is in constant 
progress. One of the reliable biomarkers that reflect the 
presence of endothelial dysfunction and T2DM is the 
Fatty Acid Binding Protein 4 (FABP4).
The limited number of studies on this issue 
was carried out only as a part of study devoted 
cardiovascular events risk. In a prospective 15-year 
study with 3700 participants, Luc Djousse with 
coauthors founded higher level of the FABP4 in patients 
with subsequently developed T2DM compared with 
patients without diabetes [5]. In this study, as well as in 
similar ones, researchers find a relationship between 
increased level of this marker and insulin resistance, 
body mass index, and level of unesterified free fatty 
acids [6], [7].
The results of experimental study in mice show, 
that decreased FABP4 level improved glucose and fat 
metabolism, reduced insulin resistance, atherogenesis 
and atherosclerosis, increased mice survival. All 
aforementioned, justified the possibility of using FABP4, 
as a potential marker of diabetes risk and monitoring its 
effectiveness treatment [8].
The analysis of clinical and experimental 
studies demonstrated the interlinks of the FABP4 
biomarker and T2DM, and a connection of the FABP4 
and cardiovascular events. However, relationships 
between increased FABP4 and risks of diabetes 
estimated by FINDRISC scale and cardiovascular 
events risk by SCORE scale have not been studied 
early. Our study team determined further interest 
in studying this topic at the stage of pre-nosological 
diagnosis to prevent fatal and non-fatal adverse 
cardiovascular events. We suggest that study of 
pathogenetic links between FABP4, prediabetes, and 
vascular catastrophes will be useful for creating early 
therapeutic strategy.
Purpose
The importance of the biomarker FABP4 to 
study, which determines the different risk of diabetes 
and cardiovascular events.
Material and Methods
Respondents
A prospective observational cross-sectional 
study of the population of Karaganda region was 
conducted simultaneously from May 2017 to December 
2019. 389 respondents aged 18–65 took part in the study. 
There were 253 women (65%) and 136 men (34.7%). 
The study included questionnaires, anthropometry 
measuring height, weight, waist circumference (WC), 
calculating body mass index (BMI), measuring blood 
pressure (BP), determining fasting glucose, serum total 
cholesterol, and FABP4 biomarker.
The exclusion criteria were the following 
categories. Patients with the previous medical history 
of acute and decompensated heart diseases, including 
myocardial infarction, brain stroke confirmed by coronary 
angiography, and CT, and patients with chronic kidney 
disease and renal dysfunction based on glomerular filtration 
rate (GFR/CKD-EPI), ≤90 ml/min/1,73 m2 were excluded 
from the study. Patients with previously diagnosed diabetes 
mellitus type 2, and diabetes newly diagnosed by per oral 
glucose tolerance test, or those with plasma glucose at 
or above 11.1 mmol/l (200 mg/dl) were excluded from the 
study. Pregnant women, people with severe mental and 
oncological diseases were excluded from the study.
Patients were divided into groups with diabetes 
risk (low and high) and control group. The control 
group consisted of 15 people aged 18–30, without any 
concomitant diseases.
Before the study, all respondents filled informed 
consent.
The ethical approval
The research team received approval from 
Local Ethical Committee of “Karaganda State Medical 
University,” Karaganda, Kazakhstan, in accordance 
with principles of Declaration of Helsinki. The study 
protocol number is 309 from May 19, 2017.
Measurement of serum FABP4 biomarker
The study of the biomarker FABP4 serum 
level was carried out using a multiplex study, 
immunofluorescence method, and XMap technology. 
For this, Bioplex 3D instrument and reagent kit 
MILLIPLEX® Human cardiovascular disease panel I 
(Millipore) were used.
Assessment diabetes risk on the 
FINDRISC scale
The risk of diabetes was assessed using 
the FINDRISC scale, questions of which included 
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information on age, BMI, waist circumference(WC), a 
daily presence of at least 30 min of physical activity, 
taking antihypertensive drugs, data on the presence 
of diabetes in relatives, increased capillary glucose 
blood, and a daily consumption of fresh vegetables [9]. 
According to this scale, the examined persons with 
number of points below 7 had a low risk of type 2 
diabetes (FINDRISС-1); from 7 to 11 points – a slightly 
increased risk of type 2 diabetes (FINDRISС-2); from 12 
to 14 points – a moderate risk of T2DM (FINDRISС-3); 
and from 15 to 20 points – a high risk of T2DM 
(FINDRISС-4); more than 20 points – a very high risk 
of T2DM (FINDRISС-5). The FINDRISC gradation data 
reflect the likelihood of developing T2DM: FINDRISC-1 
is than 1 out of 100 will have diabetes, FINDRISC-2 is 
than 1 out of 25 will have diabetes, FINDRISC-3 is than 
1 out of 6 will have diabetes, FINDRISC-4 is than 1 out 
of 3 will have diabetes, and FINDRISC-5 is than 1 out 
of 2 will have diabetes. Conventionally, all respondents 
were divided into two groups: The low and the high risk 
of T2DM. The low-risk group included respondents with 
a score of less than 11 (FINDRISС-1,2), and the high-
risk group of T2DM – more than 12 (FINDRISС-3,4,5).
Assessment CVR on the SCORE scale
The CVR SCORE was calculated using 
an online calculator with free access, and using risk 
chart [10], [11]. Questions included age, gender, smoking 
issues, blood pressure (BP), and blood cholesterol 
in mmol/l. Persons with a score of 1% or less were 
included in a low CVR group (SCORE 1), more than 
1% and <5% - in a moderate CVR (SCORE 2), from 
5% to 10% – in a high CVR (SCORE 3), over 10% – in 
a very high risk (SCORE 4). Conventionally, patients 
were divided into two groups: The low and high CVR 
(CVR). The low CVR group consisted of respondents 
with a score of less than 1% (SCORE 1), the high CVR 
group was a score over 1% (SCORE 2,3,4). This scale 
also allows to assess the risk of person death from 
cardiovascular diseases over the next 10 years.
Statistical analysis
The data were tested for normal distribution 
using Kolmogorov–Smirnov test, the distribution was 
not normal. Variables not normally distributed were 
log-transformed. Statistical significance of differences 
between groups was evaluated using non-parametric 
Mann–Whitney U-test. Differences were considered 
statistically significant at p < 0.05. The relationship 
of biomarker with the risk of diabetes and CVR was 
assessed using the Spearman correlation coefficient. 
The FABP4 associations with diabetes risk and CVR 
were calculated using a binary logistic regression 
model. The biomarker was tested in an unadjusted and 
adjusted model. Variables were logistically transformed 
before construction of regression model. Polynomial 
regression was used, studying factors affecting on the 
CVR in patients with diabetes risk. Statistical analysis 
was performed using IBM SPSS Statistics, 22.0. Results 
were considered statistically significant at p < 0.05.
Results
The low risk of T2DM (FINDRISC-1) was found 
in 166 (42.67%) respondents, the slightly increased 
risk (FINDRISC-2) was found in 129 (33.16%), the 
moderate risk (FINDRISC-3) in 33 (8.48%), the 
high risk (FINDRISC-4) in 37 (9.51%), the very high 
risk (FINDRISС-5) – in 9 (2.31%) people, and the 
control group was 15 (3.85%) respondents. Thus, 
295 (75.83%) respondents were included in the low-
risk group of T2DM (FINDRISС-1,2), and 79 (20.3%) 
respondents were included in the high-risk group of 
T2DM (FINDRISС-3,4,5) (Table 1).
In the high-risk group of diabetes, the median 
values of respondents’ age were significantly higher 
than median age in the low-risk group. Thus, median 
of respondents’ age in the high-risk group was 62 years 
old (Q25; Q75–58.0; 63.0), in the low-risk group was 
56 years (Q25; Q75–46.0; 60.0; р = 0,001).
Anthropometric characteristics of respondents, 
such as weight, BMI, WC in the group of respondents 
with the high risk of T2DM, were significantly higher 
than corresponding parameters in the low-risk group. 
In the low-risk group of T2DM, median of weight was 
71.0 kg (Q25; Q75–63.0; 81.2), BMI was 26.13 kg/m2 
(Q25; Q75–23.65; 29.05), and WC was 89.0 cm (Q25; 
Q75–81.0; 96.0), while in respondents with the high risk 
of T2DM, these indicators were: Weight – 85.8 kg (Q25; 
Q75–78.0; 94.0), BMI – 33.2 kg/m2 (Q25; Q75–30.06; 
Table 1: Baseline characteristics of respondents with the diabetes risk and cardiovascular risk
Variables Low risk of T2DM (FINDRISС-1,2) (n=295) High risk of T2DM (FINDRISС-3,4,5) (n=79) р-value
Q25 Me Q75 Q25 Me Q75
Age, years 46.0 56.0 60.0 58.0 62.0 63.0 0.001
Weight, kg 63.0 71.0 81.2 78.0 85.8 94.0 0.000
Height, cm 158.0 164.0 172.0 156.0 160.0 163.0 0.000
BMI*, kg/m2 23.65 26.13 29.04 30.06 33.25 37.04 0.000
WC, cm 81.0 89.0 96.0 97.0 104.0 109.0 0.000
Systolic BP, mm of mercury 110.0 120.0  140.0 125.0 140.0 160.0 0.000
Diastolic BP, mm of mercury 70.0 80.0 90.0 80.00 90.0 100.0 0.000
Glucose, mmol/l 5.1 5.4 5.7 5.4 5.90 6.80 0.000
Cholesterol, mmol/l 4.19 5.09 6.15 4.68 5.53 6.54 0.000
SCORE, % 0.46 0.89 3.09 1.56 2.52 4.01 0.000
*BMI: Body mass index, WC: Waist circumference, BP: Blood pressure Data presented as Me (Q25;75), cardiovascular risk SCORE more than 1% regarded as a high risk.
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33.25), WC – 104.00 cm (Q25; Q75–97.0;109.0) 
(Table 1).
The level of the blood pressure, both systolic 
and diastolic, was higher among respondents with the 
high risk of T2DM. Significant differences were found by 
the level of glucose and cholesterol in respondents with 
the high risk of T2DM, compared with similar parameters 
of the low-risk group. Not only anthropometric and 
biochemical parameters was greater in the high diabetes 
risk group but also CVR points (%) by SCORE scale. 
Accordingly, in high diabetes risk group the median of 
SCORE points comprised 2.52% and was regarded as 
a high CVR.
Issues were found that determine the risk 
of T2DM on the FINDRISC scale, so in the group 
with the high risk 55 (69.62%) of respondents used 
antihypertensive therapy three folds often compared 
to the low-risk group. Consequently, in the low-risk 
group antihypertensive therapy was used among only 
65 (20.96%) respondents (95% CI 0.586; 0.374; p = 
0.005). A daily 30-min physical activity had no significant 
differences, and it was quite high in both studied 
groups. In the group with a high risk of T2DM, presence 
of a daily physical activity was noted at 71 (89.87%) of 
respondents, and in the group with the low risk of T2DM 
the number was 278 (89.67%); (95% CI 0.077; 0.073; 
p = 0.9). A daily consumption of vegetables was slightly 
higher among respondents with the low risk of T2DM, 
and their number was 168 (54.18%), compared with 40 
(50.63%) examined persons from the high-risk group 
(95% CI 0.08; 0, 15; p = 0.4). The number of persons 
with burdened family history of T2DM was expectedly 
higher among respondents from the high risk of T2DM 
group and amounted to 38 (48.10%). In the group with 
the low risk of T2DM, the share of them was 13.22%, 
(95% CI 0.58; 0.46; p = 0.000).
A similar, statistically significant trend occurred 
in determining level of the FABP4. Hence, its level 
significantly prevailed in the high-risk group of T2DM 
(Mean ± SD; 53406.5 ± 28443.9 pg/ml; n = 79; 
p = 0.000) compared with the low-risk group (9510,8 ± 
4292,6 pg/ml; n = 295), and the control group (8161,1 ± 
3092,15 pg/ml; n = 15) (Figure 1).
Calculation of correlation coefficients reflected 
a presence of positive direct correlation between 
anthropometric, age-related factors, blood pressure, 
fasting glucose, cholesterol, and the risk of diabetes 
by FINDRISC scale. Studied marker of endothelial 
dysfunction – FABP4 positively correlated with age, 
weight, and fasting glucose. The positive strong and 
statistically significant correlation was found between 
FABP4 and BMI, WC. Association the FABP4 level with 
systolic and diastolic blood pressure, cholesterol was 
weaker than with previously listed parameters and it 
was statistically significant (Table 2).
Table 2: Binary logistic regression model. Unadjusted relative 
risk of T2DM and cardiovascular risk for the FABP4 marker
Variables Β (se) OR (95%CI) р-value
FABP4 (FINDRISC) 0,238 (0,999) 4,330 (2,717–6,901) 0,000
FABP4 (SCORE) 0,236 (0,771) 2,430 (2,161–5,443) 0,000
Dependent variable is the risk of diabetes on the FINDRISC scale and cardiovascular risk on the SCORE 
scale compared to others.
Correlation between the risk of T2DM 
(r = 0,594; р = 0,000), CVR (r = 0,242; р = 0,000) and the 
level of the FABP4 marker was established. A positive 
direct average statistically significant correlation reflects 
that the level of the FABP4 marker increased with the 
increased risk of T2DM on the FINDRISC scale, and 
CVR on the SCORE scale (Table 3). 
FABP4 level also correlated with weight 
(r = 0,350; p = 0,000), BMI (r = 0,475; p = 0,000), and 
WC (r = 0,387; p = 0,000).
Binary logistic regression model built for the 
FABP4 (OR: 4,330 [95% CI: 2,717–6,901]; p = 0,000) 
showed relationship between FABP4 and risk of T2DM on 
the FINDRISC scale, as well as presence of relationship 
between the marker being studied and the CVR 
(OR: 2.430 [95% CI: 2.161–5.443]; p = 0,000) (Table 2).
Figure 1: Level of the FABP4, depending on the different risk of diabetes. Mean values comparison of FABP4 in the different groups; significant 
p = 0.000
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The adjusted risk by gender, age, and blood 
pressure according to the regression revealed a 
relationship between the risks of diabetes and CVR 
with an increased level of FABP4(Table 4).
Table 4: Binary logistic regression model. Adjusted relative 
risk of T2DM and CVR for the FABP4 marker by gender, age, 
level blood pressure
Variables Β (se) OR (95%CI) р-value
FABP4 (FINDRISC) 1,210 (0,118) 3,330 (0,447–3,37) 0,000
FABP4 (SCORE) 0,752 (0,608) 2,121 (0,644–6,988) 0,000
Dependent variable is the risk of diabetes on the FINDRISC scale and cardiovascular risk on the SCORE 
scale compared to others.
We found factors affecting on the CVR in 
patients with the risk of T2DM. Indicators such as a total 
score on the FINDRISC scale, BMI, WC, and fasting 
glucose were established. Thus, an increase in the 
FINDRISC scores increases the CVR by 2.2 times, an 
increase of glucose level increases the CVR by 2.06 
times, an increase of BMI by 1.2 times, and of WC by 
1.0 times (Table 5).
Table  5:  Polynomial  regression.  Factors  affecting  on  the 
cardiovascular risk on the SCORE scale in patients with the 
risk of T2DM
Variables Β (se) OR (95%CI) р-value
FINDRISC 0,826 2,284 (1,472–3,542) 0,000
Glucose, mmol/l 0,726 2,067 (1,097–3,898) 0,025
BMI, kg/m2* 0,223 1,249 (0,660–2,365) 0,04
WC, cm 0,040 1,041 (0,968–1,119) 0,02
*BMI: Body mass index, WC: Waist circumference.
Discussion
This prospective cross-sectional study allowed 
us to identify groups of patients with the different risk 
of T2DM on the FINDRISC scale, and the different 
CVR on the SCORE scale. In addition, data allowed to 
establish an increase of FABP4 level in both group in 
high-risks of diabetes and cardiovascular events.
The study results demonstrated a 
predominance of the moderate and high risk in the 
structure of T2DM. In Karaganda region one out 
of five respondents had the high risk of diabetes 
(FINDRISС-3,4,5), which accounted 20%. Comparative 
characteristics of respondents with FINDRISС-3,4,5 in 
the Republic of Kazakhstan are comparable with results 
of similar epidemiological studies in Saudi Arabia 
(10.7%) and Libya (12.3%), but lower than in Norway 
(28.5%), in Cuba (26.8%), and Mexico (28.9%) and also 
in similar study which was conducted in the Kazakhstan 
from 2014 to 2016 [12], [13], [14], [15]. The 10-years 
risk of T2DM in Saudi Arabia (29.4%), Libya (32.2%), 
and Hungary (41.0%) significantly exceeded the same 
indicator in Kazakhstan [12], [13], [14], [15]. Pakistani 
immigrants in Norway had a maximum percentage of 
the high diabetes risk representing about 53% [15]. 
Studies devoted evaluation of the of cardiovascular 
events risk by the SCORE scale in patients at the stage 
of prediabetes on the FINDRISC scale have not been 
conducted.
We revealed the prevalence anthropometric 
characteristics of median values with the highest values 
of weight, WC, BMI, and reflecting Grade 3 obesity in 
the high-risk group of T2DM, which is comparable with 
general statistics, and emphasizes their significance 
in the development of T2DM [16]. Correlation analysis 
determined a positive average correlation (r = 0.59) 
between FABP4 biomarker and different risk of T2DM. 
Therefore, with an increased in the level of this marker, 
the diabetes risk on the FINDRISC scale increases and 
reflects a presence of endothelial dysfunction in these 
patients at the stage of absence impaired carbohydrate 
metabolism, using standard techniques (fasting 
blood glucose, glucose tolerance test, and glycated 
hemoglobin). At the same time, an increase in the 
FABP4 biomarker level begins to increase significantly 
already in the FINDRISC 3 respondent group.
The FABP4 level correlated with such risk 
factors of T2DM as increased WC and BMI, which 
emphasizes the influence of these factors on the 
development of endothelial dysfunction and confirms 
importance of insulin resistance in its genesis. 
According to results of the study, the growth of systolic 
blood pressure, and level of the FABP4, reached higher 
values in the FINDRISC 3,4,5 group, which is similar 
with results of the previous studies and evidenced a 
presence of endothelial dysfunction [17], [18]. The 
risk of increasing FABP4 marker persists even after 
adjusting it for age, sex, and blood pressure, which 
indicates possibly a greater significance of carbohydrate 
metabolism disturbance in the development of 
endothelial dysfunction. Performed correlation between 
hyperglycemia, hypercholesterolemia, blood pressure, 
and FABP4 level indicates on a presence of vascular 
wall damage and start of cascade metabolic reactions 
in patients with diabetes risk.
The diabetes risk on the FINDRISС scale 
increases in 4.3-fold with an increase of the level 
FABP4, it is consistent with studies conducted 
previously, which prospectively proved a more frequent 
occurrence of T2DM in individuals with an increase 
level of endothelial dysfunction marker [5], [7], [16], 
[17], [19]. An increase of the level FABP4 and reaching 
its maximum values in the groups high and very high 
Table 3: Correlation between the FABP4 level, glucose, 
cholesterol, anthropometric indicators; the risk of T2DM on the 
FINDRISC scale and cardiovascular risk on the SCORE scale. 
Spearman’s correlation coefficient (r)
Variables FABP4 pg/ml in the risk group T2DM - (r)
FABP4, pg/ml* -
Age, years 0,231**
Weight, kg 0,350**
Height, cm −0,253**
BMI, kg/m2 0,475**
WC, cm 0,387**
Systolic BP, mm of mercury 0,172**
Diastolic BP, mm of mercury 0,117*
Glucose, mmol/l 0,265**
Cholesterol, mmol/l 0,109*
FINDRISC, (points) 0,594**
SCORE, (%) 0,242**
**р < 0,0001, *р < 0,05. *FABP4: Fatty acid binding protein, BMI: Body mass index, WC: Waist 
circumference, BP: Blood pressure.
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CVR was found, during studying the CVR in patients 
with the risk of T2DM.
A 12-year prospective study by Wing Sun Chow 
and coauthors reported that the FABP4 biomarker was 
a predictor of cardiovascular events in 182 (9.9%%) out 
of 1847 obese patients with a high level of the FABP4 
cardiovascular events, with median observational period 
of 9.4 years [17]. Prognostic power of this marker was 
studied in combination with С-reactive protein, reflecting 
a presence of systemic inflammatory response.
The CVR using the Framingham scale was 
assessed in a prospective study named «Monitoring of 
Trends and Determinants in Cardiovascular Disease» 
(MONICA), conducted by Koenig et al. After 6.6 years of 
follow-up, the percentage of cardiovascular events was 
slightly lower and consisted of 191 (5.6%) out of 3435 
patients [20]. The previous researches also identified factors 
determining the CVR in these patients; they have a high 
BMI, WC, systolic BP, diastolic BP, hyperglycemia, insulin 
resistance index (HOMA), and dyslipidemia [17], [21]. 
Thus, we can say that the FABP4 biomarker is a predictor 
of diabetes risk and cardiovascular events.
Conclusions
1. The level of the FABP4 significantly increased 
in both group with high risks of diabetes and 
cardiovascular events. FABP4 was associated 
with such factors as increased WC, BMI, and 
fasting hyperglycemia.
2. The established relationship between the 
level of FABP4 and the risks of diabetes and 
cardiovascular events evidences, its increase 
with rising points on the FINDRISC and 
SCORE scales, and reaches a peak in the high 
risk groups. Nevertheless, further monitoring 
of patients is necessary to determine the 
diagnostic importance of FABP4 as a predictor 
of the development cardiovascular events and 
diabetes mellitus.
3. The high level of the FABP4 in respondents with 
high risks of diabetes and cardiovascular events 
determines the importance of planning clinical 
strategy for the early identification of this category 
of people and targeted therapeutic effects, 
which will prevent the development of T2DM 
with a progression of endothelial dysfunction 
and reduce the further cardiovascular events.
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